Stray Dog

HIMS valuation, international growth and Q1 preview

  • Good news: Price-to-sales is about 2x against a historical median of 3.3x; a return to the median implies a share price above $30.
  • Good news: International revenue was $134 million in 2025, up about 400%, with a target of $1 billion within 3 years.
  • Mixed: Q1 revenue guidance is $600-625 million, held back by a one-off GLP-1 regulatory hit of about $65 million.
Read the full notes

Analyst consensus

Average price target

$31.71

Coverage

17 analysts

Current price

About $28

Peptide blind spot

Most analyst models do not yet include peptide revenue. BofA says explicitly that peptides are pure upside.

Upside to consensus

About 13%

International business

2025 revenue

$134 million (up about 400% year on year)

Acquisitions
  • ZAVA
  • Livewell
Eucalyptus markets
  • Australia
  • Japan
  • UK
  • Germany
  • Canada
Management target

$1 billion of international revenue within 3 years

Q1 earnings preview

Adjusted EBITDA margin guidance

6-9%

Date

11 May, after the close

Reason for growth slowdown

A one-off regulatory hit to GLP-1 (a revenue headwind of about $65 million)

Revenue guidance

$600-625 million (+2.4% to 6.7% YoY)

Watchpoints
  • Novo conversion rate
  • Resilience of the non-GLP-1 businesses
  • Progress at Labs

Valuation snapshot

Implication

A return to the median implies a share price above $30. The market's repricing has only just begun.

Current P/S ratio

About 2x

Historical median P/S ratio

3.3x

Weekly move

Up about 35-48% last week